GatlinA. BioMarin surges as activist investor Elliott reportedly builds $1 billion stake. Investor's Business Daily; 2023. Available from: https://www.investors.com/news/technology/bmrn-stock-rockets-as-activist-investor-reportedly-builds-stake/ (Last accessed: November10, 2023).
3.
Sangamo Therapeutics. Sangamo Therapeutics announces strategic update and reports third quarter 2023 financial results. 2023. Available from: https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-announces-strategic-update-and-reports-0 (Last accessed: November10, 2023).
4.
AstraZeneca and Cellectis. AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions. 2023. Available from: https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy-deal-w-cellectis.html (Last accessed: November11, 2023).
5.
Forge Biologics. Ajinomoto Co., Inc., to acquire forge biologics for $620 million. 2023. Available from: https://www.forgebiologics.com/ajinomoto-co-inc-to-acquire-forge-biologics-for-620-million1/ (Last accessed: November13, 2023).
6.
Bluebird Bio. Bluebird bio enters into advance agreement to sell priority review voucher, if granted, for $103 million. 2023. Available from: https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-enters-advance-agreement-sell-priority-review (Last accessed: November11, 2023).
7.
Lexeo Therapeutics. Form 424B4, prospectus, filed. 2023. Available from: https://ir.lexeotx.com/static-files/b67b37c2-24d0-476a-ac4b-fa20aa3c3160 (Last accessed: November10, 2023).
8.
U.S. Food and Drug Administration. FDA Briefing Document, BLA# 125787/0, exagamglogene autotemce, Vertex Pharmaceuticals Inc. 2023. Available from: https://www.fda.gov/media/173414/download (Last accessed: November11, 2023).
9.
DaviesK. CRISPR prime time? FDA advisory committee evaluates vertex exa-cel therapy for sickle cell disease. Genetic Engineering & Biotechnology News; 2023. Available from: https://www.genengnews.com/topics/genome-editing/crispr-prime-time-fda-advisory-committee-evaluates-vertex-exa-cel-therapy-for-sickle-cell-disease/ (Last accessed: November11, 2023).
10.
MeiraGTx. MeiraGTx announces $30 million strategic investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities; 2023. Available from: https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-announces-30-million-strategic-investment-sanofi (Last accessed: November11, 2023).
